Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.

ABSTRACT: Late stage or aggressive cancers exhibit metastatic growth at multiple sites, and the characterization of treatment response in various organs to drugs with potentially wide-ranging efficacy is needed. Tumor cells that induce angiogenesis are a common characteristic of metastatic disease, and clinically, antiangiogenic therapies have shown value in the setting of advanced cancer. However, recent preclinical studies have suggested that exposure to antiangiogenic drugs can increase tumor invasiveness and metastasis, making it important to determine which contexts antiangiogenic therapy is most appropriate. We describe here the effects of cediranib, a receptor tyrosine kinase inhibitor, in a model of advanced prostate cancer metastatic to skeleton and brain. Treatment with cediranib decreased

SUBMITTER: Yin JJ 

PROVIDER: S-EPMC2989818 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature